SRX has had a bad year with disclosure scandals, class actions and underwhelming trial results. The board has been too busy running around like headless chooks, instead of taking over OSL. It seems like a good fit for them, they already have the distribution and marketing network and it would give them a new growth avenue.
Ann: Progress Update on Global Pancreatic Cancer Clinical Study, page-18
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.99M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.6¢ | $1.536K | 256K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2163512 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 20140788 | 23 |
View Market Depth
| Last trade - 10.06am 03/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |